Kitonail

Ciclopirox, the active ingredient in Kitonail, is an antifungal presented as a topical formulation for external use. It is employed to treat fungal infections of the nail and skin, including onychomycosis and various tinea conditions, in adult patients, and is indicated for both superficial and deep fungal infections, providing a broad spectrum of activity.

GNH USA supplies Kitonail as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across all markets.

Kitonail (ciclopirox) is used to manage fungal infections of the nail and skin, targeting dermatophytes and yeasts.

Onychomycosis: reduces fungal load and promotes nail regrowth. Tinea corporis: alleviates skin lesions and prevents spread. Tinea pedis: relieves itching and clears infection of the feet. Tinea cruris: treats fungal infection of the groin area and reduces inflammation.

Topical ciclopirox may cause local skin reactions, ranging from mild irritation to rare severe events.

Common Side Effects: - Application site erythema: redness at the site of application. - Pruritus: mild itching. - Scaling: flaking of skin. - Dryness: localized skin dryness. - Burning sensation: transient warmth.

Serious or Rare Side Effects: - Severe contact dermatitis: intense rash and swelling. - Allergic reaction: hives or systemic urticaria. - Excessive skin ulceration: breakdown of skin at the application site.

When using Kitonail, consider the following precautions to ensure safe and effective therapy.

Avoid use on compromised skin: do not apply to open wounds or severe eczema. Limit occlusion: avoid covering treated area with airtight dressings unless directed. Monitor for irritation: discontinue if severe redness or swelling occurs. Pregnancy and lactation: consult healthcare professional before use. Store at ambient temperature: keep in original container, protect from moisture and light.

Ciclopirox may interact with other topical agents or systemic medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent use with other topical antifungals: may increase local irritation. - Application with corticosteroid creams: can reduce antifungal efficacy.

Moderate Interactions (Monitor Closely): - Use with occlusive dressings: may enhance absorption and irritation. - Systemic antifungal therapy (e.g., oral terbinafine): monitor for additive effects. - Chemotherapeutic agents applied to skin: observe for increased skin sensitivity.